Venus Remedies Limited (VENUSREM) AI Stock Analysis

1 Followers

Venus Remedies Limited

(NSE:VENUSREM)

Select Model

Rating:69Neutral

Price Target:INR 1,571.00▲(9.52% Upside)

Action:downgraded

Date:10/31/26

Strong financial performance is the primary support, reinforced by reasonable valuation. However, the stock is trading below all major moving averages with negative MACD, making weak technical momentum the main constraint on the overall score.

Positive Factors

Improving Revenue GrowthThe return to sustained revenue growth indicates improving commercial traction across the company’s pharmaceutical portfolio after the 2023 decline. Continued top-line expansion can support operating leverage, strengthen market reach, and provide a durable base for earnings growth over coming quarters.

Negative Factors

Unclear Margin SustainabilityThe absence of 2026 margin detail makes it harder to determine whether the substantial earnings increase reflects durable operating improvement or a less persistent change in profitability. Uncertain margin sustainability reduces confidence in the earnings trajectory over the next several quarters.

Venus Remedies Limited (VENUSREM) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 18.98B
Dividend Yield: 0.70%
Average Volume (3M): 3,792
Price to Earnings (P/E): 15.9
Beta (1Y): 0.96
Revenue Growth: 20.22%
EPS Growth: 73.03%
Country: India
Employees: 1,472
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Venus Remedies Limited Business Overview & Revenue Model

Company Description

Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spect...

Venus Remedies Limited Financial Statement Overview

Summary

Strong revenue and profit growth, improved margins, very low leverage, and better operating and free cash flow support a robust financial profile. Historical volatility in growth and cash generation limits the score.

Income Statement

86Very Positive

Balance Sheet

90Very Positive

Cash Flow

82Very Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	8.11B	7.70B	6.48B	5.91B	5.56B	5.99B
Gross Profit	3.25B	2.68B	1.66B	2.18B	2.25B	2.00B
EBITDA	1.75B	1.60B	944.10M	711.80M	703.46M	701.40M
Net Income	1.16B	1.03B	453.20M	284.91M	265.70M	407.24M
Balance Sheet
Total Assets	0	8.54B	7.16B	6.27B	6.01B	5.80B
Cash, Cash Equivalents and Short-Term Investments	1.03B	1.04B	1.64B	838.05M	720.77M	432.56M
Total Debt	0	124.10M	16.90M	413.25M	422.90M	428.45M
Total Liabilities	-6.64B	1.90B	1.55B	1.39B	1.41B	1.39B
Stockholders Equity	6.64B	6.64B	5.61B	4.88B	4.60B	4.40B
Cash Flow
Free Cash Flow	682.20M	1.20B	812.90M	278.40M	288.02M	272.94M
Operating Cash Flow	811.10M	1.57B	909.20M	372.85M	366.20M	410.01M
Investing Cash Flow	-1.27B	-1.84B	-807.90M	-72.09M	-508.30M	-166.26M
Financing Cash Flow	126.70M	-25.30M	-9.50M	-10.83M	-5.70M	-94.77M

Venus Remedies Limited Technical Analysis

Technical Analysis SentimentNeutral

Last Price1434.45

Price Trends

50DMA1568.07Negative

100DMA1635.02Negative

200DMA1302.71Positive

Market Momentum

MACD-53.36Negative

RSI46.33Neutral

STOCH73.65Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Neutral. The current price of 1434.45 is below the 20-day moving average (MA) of 1439.60, below the 50-day MA of 1568.07, and above the 200-day MA of 1302.71, indicating a neutral trend. The MACD of -53.36 indicates Negative momentum. The RSI at 46.33 is Neutral, neither overbought nor oversold. The STOCH value of 73.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:VENUSREM.

Venus Remedies Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:VENUSREM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:SYNCOMF	83Outperform	INR 18.85B	22.38	―	0.49%	0.44%	48.60%
IN:VENUSREM	69Neutral	INR 19.37B	15.86	―	0.70%	20.22%	73.03%
IN:LINCOLN	67Neutral	INR 10.43B	10.80	―	0.35%	14.25%	21.11%
IN:WINDLAS	66Neutral	INR 20.15B	31.25	―	0.63%	18.48%	-0.41%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:INDSWFTLAB	51Neutral	INR 30.39B	37.21	―	―	66.39%	-72.31%
IN:INDOCO	48Neutral	INR 20.25B	64.56	―	0.09%	10.75%	―

* General Sector Average

Performance Comparison

IN:VENUSREM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:VENUSREM	Venus Remedies Limited	1434.45	873.17	155.57%
IN:INDOCO	Indoco Remedies Limited	219.95	-46.77	-17.53%
IN:INDSWFTLAB	Ind-Swift Laboratories Ltd.	362.20	259.40	252.33%
IN:LINCOLN	Lincoln Pharmaceuticals Ltd	521.10	17.38	3.45%
IN:SYNCOMF	Syncom Formulation (India) Ltd.	20.37	3.78	22.80%
IN:WINDLAS	Windlas Biotech Ltd.	999.40	172.60	20.88%

Venus Remedies Limited Corporate Events

Venus Remedies Secures Shareholder Approval for All Resolutions at 37th AGM

Aug 21, 2026

Venus Remedies Limited has announced that all 12 resolutions proposed at its 37th Annual General Meeting, held on August 20, 2026 via video conferencing, were approved by the requisite majority under SEBI listing regulations and the Companies Act. Th...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

Venus Remedies Limited AI Stock Analysis